更新于：2024-09-19

OXCT1

更新于：2024-09-19

基本信息

别名

3-oxoacid CoA-transferase 1、OXCT、OXCT1

+ [5]

简介

Key enzyme for ketone body catabolism. Catalyzes the first, rate-limiting step of ketone body utilization in extrahepatic tissues, by transferring coenzyme A (CoA) from a donor thiolester species (succinyl-CoA) to an acceptor carboxylate (acetoacetate), and produces acetoacetyl-CoA. Acetoacetyl-CoA is further metabolized by acetoacetyl-CoA thiolase into two acetyl-CoA molecules which enter the citric acid cycle for energy production (PubMed:10964512). Forms a dimeric enzyme where both of the subunits are able to form enzyme-CoA thiolester intermediates, but only one subunit is competent to transfer the CoA moiety to the acceptor carboxylate (3-oxo acid) and produce a new acyl-CoA. Formation of the enzyme-CoA intermediate proceeds via an unstable anhydride species formed between the carboxylate groups of the enzyme and substrate (By similarity).

关联

100 项与 OXCT1 相关的临床结果

登录后查看更多信息

100 项与 OXCT1 相关的转化医学

登录后查看更多信息

0 项与 OXCT1 相关的专利（医药）

登录后查看更多信息

369

项与 OXCT1 相关的文献（医药）

2024-12-01·Molecular Biology Reports

Silver nanoparticle-induced in vitro flowering in Dendrocalamus strictus (Roxb.) nees and genetic fidelity assessment of regenerants using molecular markers

Article

作者: Shekhawat, Mahipal S ; Manokari, M ; Faisal, Mohammad ; Sandhya, Dulam ; Alatar, Abdulrahman A ; Solanki, Nitin J ; Rajput, Bharat Singh

BACKGROUNDDendrocalamus strictus (Roxb.) Nees, generally referred to as 'Male bamboo,' is a globally prevalent and highly significant species of bamboo. It is a versatile species and possesses notable industrial significance. However, despite its numerous applications, the production of this plant is insufficient to fulfill the worldwide demand. The challenges that impede the dissemination of D. strictus encompass the unpredictable blooming pattern (30-70 years), low seed production, and limited seed viability. Therefore, tissue culture presents a reliable and effective option for the mass production of standardized planting material.METHODOLOGY AND RESULTSThis study investigated the effects of silver nanoparticles (AgNPs) at a concentration of 6.0 mg L^- 1 in the Murashige and Skoog (MS) nutrient medium fortified with pre-optimized plant growth regulators (3.0 mg L^- 1 6-benzylaminopurine + 0.5 mg L^- 1 α-naphthalene acetic acid) on the induction of flowering in a controlled environment in D. strictus. The use of AgNPs in the media induced a maximum of 14 inflorescences per culture vessel, 9 flowers per inflorescence, and improved the performance of the micropropagated plantlets during acclimatization in the greenhouse and field. The ISSR and SCoT amplified polymorphic DNA analysis of the regenerants resulted in the formation of 49 bands (300 to 2000 bp size) and 36 scorable bands (350 to 2000 bp) respectively. All the PCR amplicons produced by SCoT and ISSR were monomorphic confirming the genetic uniformity of the tissue cultured plants of D. strictus with the mother plant.CONCLUSIONSIt can be inferred that the incorporation of AgNPs during the shoot proliferation phase has the potential to stimulate in vitro flowering in D. strictus. This finding could provide valuable insights into innovative strategies for enhancing crop productivity and genetic manipulation for accelerated breeding and agricultural advancement.

2024-09-01·Journal of Proteomics

The effect of the production system on the proteomics profiles of the Longissimus thoracis muscle in Arouquesa cattle

Article

作者: Dittmann, Antje ; Sacarrão-Birrento, Laura ; Ribeiro, David M ; Kunz, Laura ; de Almeida, André M ; Alves, Susana P ; Venâncio, Carlos A ; Silva, Severiano

Arouquesa cattle breed is an autochthonous Portuguese breed produced under a traditional mountain system that need improvement without affecting beef quality. The aim of this work is to compare the proteomics profiles of the Longissimus thoracis muscle from Arouquesa animals produced under different production systems. Sixty weaners were produced under the following systems: traditional (TF) and traditional with starter feed supplementation (TF + S1) with weaning and slaughtering at 9 months, the S1 + S2 (weaning at 5 months and grower supplement until slaughter) and two rearing periods with finishing supplementation (TF + S3 and S3). Upon slaughter, samples of L. thoracis were taken and analyzed using a shotgun proteomics workflow. Several putative markers of beef quality for the Arouquesa breed were identified: VIM, FSCN1, SERPINH1, ALDH1A1, NDUFB5, ANXA1, PDK4, CEMIP2, NDUFB9, PDLIM1, OXCT1, MYH4. These proteins are involved in actin binding, skeletal muscle development and in the mitochondrial respiratory chain and they can influence mostly meat tenderness and color. We identified specific proteins for each group related to different metabolisms involved in several aspects that affect meat quality parameters. Our results demonstrate the link between production practices and putative meat characteristics, which have the potential to improve the traceability of certified products. SIGNIFICANCE: Arouquesa breed is produced in a sustainable system using natural resources and contributing to the economy of low-populated rural regions in Northern Portugal. Besides their economic relevance, producing autochthonous breeds can counter rural depopulation and maintain local heritage. Additionally, consumer awareness about product quality is increasing and PDO products contribute to satisfying this demand. However, it is necessary to increase production so that it is possible to sell these products outside the production region. To ensure robust traceability and that PDO label characteristics are maintained despite increasing production yield, product analysis is of paramount importance. For this reason, proteomic approaches can provide insight into how production changes will affect beef quality and generate putative biomarkers of certified production systems.

2024-08-01·Arthritis & Rheumatology

Outcomes of Patients With Diffuse Systemic Sclerosis Eligible for Autologous Stem Cell Transplantation Treated With Conventional Therapy

Article

作者: Sahhar, Joanne ; Tymms, Kathleen ; Hansen, Dylan ; Youssef, Peter ; Stevens, Wendy ; Ross, Laura ; Cooley, Helen ; Host, Lauren ; Penglase, Ross ; Ngian, Gene‐Siew ; Gregory, Kate ; Proudman, Susanna ; Moore, John ; Apostolopoulos, Diane ; Walker, Jennifer ; Ferdowsi, Nava ; Morrisroe, Kathleen ; Nikpour, Mandana

ObjectiveThe study objective was to determine the event‐free survival (EFS) of Australian patients with diffuse cutaneous systemic sclerosis (dcSSc) who met eligibility criteria for autologous stem cell transplant (ASCT) in previously published randomized controlled trials but were not treated with ASCT.MethodsPatients who met inclusion criteria for the Autologous Stem Cell Transplantation International Scleroderma (ASTIS) and Scleroderma: Cyclophosphamide Or Transplantation (SCOT) trials were identified from the multicenter Australian Scleroderma Cohort Study (ASCS). EFS (survival without cardiac, renal, or pulmonary failure or death) at 4 years was assessed. ASCS patients who had already undergone transplantation were excluded from analysis.ResultsOf the 492 patients with dcSSc in the ASCS, 56 met ASTIS inclusion criteria for ASCT (56 of 492 [11.4%]) and 30 met SCOT inclusion criteria (30 of 492 [6.1%]). An additional 11 patients met ASTIS or SCOT inclusion criteria, but they were excluded due to severe organ manifestations. EFS at 4 years in ASCS patients meeting ASTIS inclusion criteria was 83.3% and in ASCS patients meeting SCOT inclusion criteria was 81.2%. EFS at 4 years in ASCS patients who met ASTIS and SCOT inclusion but also exclusion criteria was 46.7% and 45.7%, respectively.ConclusionASCS patients meeting ASTIS and/or SCOT inclusion criteria who were not treated with ASCT have similar EFS at 4 years as patients receiving ASCT and better EFS than those receiving cyclophosphamide in the ASTIS and SCOT trials. This may reflect confounders unable to be controlled for, including survivor bias, but may also reflect improved standard of care for dcSSc over time.

项与 OXCT1 相关的新闻（医药）

2023-01-17

·生物制药小编

老药新用 | 精神病药物或可用于二型糖尿病

近年来，随着我国肥胖人口的不断增多，二型糖尿病的需求也变得越来越大。虽说“神药”二甲双胍是这些二型糖尿病最常用的治疗药物之一，但大约15%的患者不能服用。而另一种治疗方法——胰岛素促分泌素则对晚期患者并不有效。因此寻找一种可能具有一定作用的潜在疗法或联用疗法相当重要。然而，近年来，开发一款新药的成本并不便宜，而且一些新药的定价也不便宜，例如，之前批准的CD3单抗价格昂贵，也因此，不少利用新技术进行老药新用也被提上了日程。研究人员首先从机理出发，他们观察到骨骼肌琥珀酰辅酶a:3-酮酸辅酶a转移酶(SCOT)活性(这是一种酮氧化的限速酶)的升高是导致以肥胖和T2D为特征的高血糖症的诱因。利用这一机理，他们开始寻找可能与SCOT发生潜在相互作用的药物，并最终找到了一类抗精神病老药——二苯基丁基哌啶或称DPBPs。发现过程此类药物的作用机理与吩噻嗪类的作用机理类似，但除了吩噻嗪类所具有的中枢多巴胺能神经抑制作用（是一种多巴胺受体2拮抗剂）之外还有钙离子通道的抑制作用。此外由于此类药物吸收分布代谢过程周期较长，因此其口服的作用时间很长，是一类长效口服抗精神分裂药物。从结合模式中确定二苯基丁基哌啶类药物可能与SCOT发生潜在相互作用后，研究人员通过在雄性肥胖小鼠中采取了三种药物进行治疗，结果发现，三种二苯基丁基哌啶类药物——匹莫齐特、五氟利多和氟司必林，都改善了肥胖小鼠的血糖稳态。（如下图所示）有趣的是，研究人员还采取了另外一种多巴胺受体2拮抗剂鲁拉西酮进行急性或慢性治疗，却没有降糖作用。这表明，DPBP介导的肥胖诱导的高血糖症的缓解完全依赖于DPBPs抑制SCOT的能力。（如下图所示）总结由于DPBPs在人类中似乎相对安全，之前已被批准用于治疗精神分裂症/精神病。虽然如果具体使用上海需要仔细监测循环中的酮，这类药物还是可能有助于重新用于治疗二型糖尿病的。参考文献：Seyed Amirhossein Tabatabaei Dakhili, Amanda A. Greenwell, Kunyan Yang, Rabih Abou Farraj, Christina T. Saed, Keshav Gopal, Jordan S.F. Chan, Jadin J. Chahade, Farah Eaton, Crystal Lee, Carlos A. Velázquez-Martínez, Peter A. Crawford, J.N. Mark Glover, Rami Al Batran, John R. Ussher; The Antipsychotic Dopamine 2 Receptor Antagonist Diphenylbutylpiperidines Improve Glycemia in Experimental Obesity by Inhibiting Succinyl-CoA:3-Ketoacid CoA Transferase. Diabetes 1 January 2023; 72 (1): 126–134. https://doi-org.libproxy1.nus.edu.sg/10.2337/db22-0221注：内容来源于网络，如有侵权，请联系删除。

药物审批

2022-06-29

·BioBAY

朗捷睿：完成5000万元天使轮融资，推进管线产品研发

BioBAY园内企业朗捷睿宣布完成5000万人民币天使轮融资，由深圳市前海万容红土领投，君尚资本、园区科创基金跟投。本轮融资将主要用于推进朗捷睿两条临床1期管线产品研发。园内企业朗捷睿成立于2020年12月28日，致力于新型代谢检查点调节剂的开发。产品聚焦于与代谢检查点密切相关的重大慢性疾病，包括肿瘤、自身免疫性疾病、神经退行性疾病、多发性动脉炎和静脉炎、衰老等方面的原创新药研发。朗捷睿始终坚持自己的愿景与使命，以健康济人道为本，以临床需求为导向，以创新驱动为引擎，以代谢检查点调节剂为主线，将公司打造成生物医药的领军企业，坚持不断创新引领，永立潮头。深圳前海万容红土投资基金表示：“朗捷睿是苏州工业园区的重大领军项目，得到了政府的高度关注和支持。其创始团队学科建制齐全，经几十年磨合，配合十分默契。核心产品覆盖了与代谢检查点密切相关的重大疾病，涉及ACAT1、SIRT2、OXCT1等靶点。我们相信，朗捷睿团队能够带领公司持续推进产品管线研发，为广大患者提供革命性的创新疗法。” 苏州工业园区科创基金管理人领军创投副总经理陈炼先生表示：“生物医药是苏州工业园区重点支持和发展的行业，代谢检查点研究是极富潜力的前沿领域。朗捷睿集结了国内药物研发顶尖人才，深耕代谢检查点与慢性疾病发生发展的分子机制研究多年。我们看好朗捷睿能够建立国内首个代谢检查点调节剂创新药物研发平台，并依托该平台研发出多个‘first-in-class’产品，成为园区药物研发的领军企业。”推荐阅读曹雪涛、田志刚两大院士齐上阵！2022苏州国际精英创业周细胞治疗论坛即将来袭茂行生物：与谱新生物达成战略合作，加速通用型细胞药物的创新与突破FDA发布最新指南草案，指导寡核苷酸疗法开发（附PDF）

合作细胞疗法寡核苷酸